Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

PFE 32.45 -0.36 (-1.10%)
price chart
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for ...
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Related articles »  
Is Pfizer A Good Buy?
Pfizer has been involved in a series of acquisitions and sell offs, some cheered and some criticized by investors. They recently sold off their nutrition business to Nestle for $11.9 billion.
Pfizer Needs Big Earnings Beat  TheStreet.com
Pfizer Defends $25 Fair Value With Lyrica Patent Lawsuit Win  Trefis
Related articles »  
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Related articles »  
Why We Think Pfizer Remains Significantly Undervalued
If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale.
Related articles »  
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Pfizer-J&J Alzheimer's Drug Fails to Aid Cognition  Bloomberg
Pfizer, J&J Alzheimer's drug fails one of four big trials  Reuters
Related articles »  
Pharmacies Sue Pfizer Over Lipitor
Five retailers joined a legal battle against Pfizer Inc., accusing the drug maker of using anticompetitive tactics to delay the introduction of competing generic copies of Pfizer's blockbuster cholesterol-lowering pill Lipitor.
Pfizer sued by retailers for generic Lipitor delay  Reuters
Walgreens, Kroger Sue Pfizer For Delay Of Generic Lipitor  Law360 (subscription)
Related articles »  
Pfizer Led Corporate America's Biggest Givers Last Year
Pfizer Inc. (PFE:US), the world's largest drugmaker, was corporate America's largest donor for a third straight year, granting $3.1 billion in gifts in 2011.
Related articles »  
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Considering lack of progress in the RNAi space to date and the fact that the drug, ALN-TTR02, is one the company's biggest pipeline hopes, this makes encouraging news, particularly as a phase II study has already started.
Related articles »  
Cost-Cutting Helps Pfizer Beat Analysts' Expectations
Timothy Anderson, an analyst at Sanford C. Bernstein & Company, wrote to investors that Pfizer's strong profit was primarily a result of better revenue, better gross margins and lower selling, general and administrative spending.
Pfizer's Cost-Cuts Offset Loss of Lipitor  Wall Street Journal
Pfizer 2Q net income rises 25 pct on lower costs  Medical Xpress
Related articles »  
Generic Lipitor: Retailers Accuse Pfizer Of Delaying Sales Of Cheap, Generic ...
TRENTON, N.J. -- Five large drug and grocery chains are suing Pfizer Inc. and a second drugmaker, alleging they conspired to delay sales of cheap generic versions of the blockbuster cholesterol drug Lipitor.
Report: Five pharmacies sue Pfizer over Lipitor  Michigan Business Review - MLive.com
Related articles »